Gut Microbiota Mediates the Anti-Obesity Effects of Gnaphalium Affine Methanol Extract in HFD-Induced Obesity

Why It Matters

GAE demonstrates a microbiota‑mediated, multi‑target strategy for obesity, positioning it as a promising functional‑food ingredient for metabolic health.

Key Takeaways

• GAE reduced HFD‑induced weight gain and adiposity
• GAE improved glucose tolerance and lipid profiles
• GAE restored gut barrier proteins ZO‑1, Occludin, Claudin‑1
• GAE enriched beneficial bacteria Lactobacillus and Phascolarctobacterium
• FMT with GAE‑modulated microbiota transferred anti‑obesity effects

Pulse Analysis

Obesity remains a leading driver of chronic disease, prompting a search for interventions that go beyond calorie restriction. Recent preclinical work on *Gnaphalium affine* methanol extract (GAE) highlights a novel avenue: leveraging plant‑derived compounds to remodel the gut ecosystem. By simultaneously delivering flavonoids, phenolic acids, and bioactive lipids, GAE attenuates oxidative stress and restores tight‑junction integrity, curbing the low‑grade inflammation that fuels insulin resistance. This dual action—direct metabolic support and barrier reinforcement—sets GAE apart from conventional antioxidants.

The gut microbiota emerges as the central conduit of GAE’s benefits. High‑throughput 16S rRNA sequencing and untargeted metabolomics identified a shift toward health‑associated genera such as *Lactobacillus* and *Phascolarctobacterium*, alongside increased levels of lysophosphatidylcholine 22:6 and N‑oleoyl glycine. These metabolites are known to modulate lipid absorption and signaling pathways linked to energy homeostasis. Importantly, fecal microbiota transplantation demonstrated causality: mice receiving microbiota from GAE‑treated donors exhibited reduced adiposity and improved hepatic markers, confirming that the microbial community alone can recapitulate the therapeutic effect.

From a commercial perspective, GAE offers a compelling functional‑food candidate. Its natural origin aligns with consumer demand for plant‑based, clean‑label solutions, while the mechanistic data provide a strong scientific narrative for regulatory approval and market differentiation. Future research should isolate the most potent constituents, assess dose‑response relationships, and initiate human trials to validate translatability. If successful, GAE could become a cornerstone ingredient in next‑generation weight‑management products, addressing obesity through a microbiota‑centric, systems‑biology approach.